Research programme: T-cell therapies - TCR2 Therapeutics

Drug Profile

Research programme: T-cell therapies - TCR2 Therapeutics

Alternative Names: TC 210; TCR fusion construct T-cell therapies - TCR2 Therapeutics; TRuC™ T-cells

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TCR2 Therapeutics
  • Developer Ludwig-Maximilians-University; Massachusetts General Hospital; TCR2 Therapeutics; University of Freiburg
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 06 Sep 2017 Pharmacodynamics data from a preclinical trial in Haematological malignancies and Solid tumours presented at the 3rd International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)
  • 13 Jun 2017 Preclinical trials in Haematological malignancies in USA (Parenteral)
  • 13 Jun 2017 Pharmacodynamics data from preclinical trials in Solid tumours released by TCR2 therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top